Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Claims Implying Supplement Could Replace Insulin Must Go, NAD Says

This article was originally published in The Tan Sheet

Executive Summary

Implying that's glucose-metabolism supplement Cinnergen is a replacement for normal insulin regimens is misleading, the National Advertising Division says

You may also be interested in...

Redline Princess Claims Must Be Backed By Product-Specific Studies – NAD

Vital Pharmaceuticals must modify advertising for its Redline Princess women's energy drink because there is no evidence the product would "enhance mood, energy and fat loss," according to the National Advertising Division

NAD refers eFoodSafety to FTC

The National Advertising Division refers to the Federal Trade Commission for possible law enforcement action for Internet advertising claims the firm made about its Cinnergen dietary supplement. As part of its routine monitoring program, NAD targeted Cinnergen for health-related establishment and performance claims including: "clinically proven to control blood sugar" and "over half the patients in our clinical study were able to stop taking prescribed medication!" according to a Feb. 7 decision. The Council of Better Business Bureaus group's numerous attempts to contact eFoodSafety were unsuccessful, NAD says...

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts